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2. SYNOPSIS 
Trial Title Rapid Urine-Based Screening for Tuberculosis to Reduce AIDS-
Related Mortality in Hospitalized Patients in Africa (STAMP) Trial 
Short title STAMP Trial 
Trial Design A multi-country (Malawi and South Africa) individually 
randomised clinical trial with two study arms (1:1 recruitment) 
 
Trial Participants HIV-infected adult patients requiring acute admission to hospital 
medical wards at clinical trial sites: 
a) Zomba Central Hospital, Zomba, Malawi. 
b) Edendale Regional Hospital, Pietermaritzburg, KwaZulu-Natal, 
South Africa. 
 
Planned Sample 
Size 
1,300 patients per arm 
Follow up duration 
 
56 days post-randomisation 
Planned 
recruitment period 
 
August 2015-July 2017 
 Objectives Outcome Measures/Endpoints 
1. Primary 
 
To determine the impact on all-
cause mortality of the addition of 
rapid, high sensitivity urine-
based TB screening to the 
standard of care TB screening in 
HIV-infected patients requiring 
admission to medical wards in 
hospitals in southern Africa 
 
 
Risk of death at 56 days after 
randomisation from any cause, 
compared between arms. 
 
2. Secondary 
 
To determine the impact of 
additional urine-based TB 
screening versus standard of 
care on: 
 
2.1 time to death from any cause 
 
2.2 the yield of TB diagnoses 
that are (a) microbiologically 
confirmed disease or (b) 
clinically diagnosed disease 
(see definitions in section 
8.6). 
 
2.3 time to (a) TB diagnosis and 
(b) start of TB treatment (see 
definitions in section 8.6) 
 
2.4 use of other medical 
interventions, including (a) 
antibacterial treatment (b) 
antiretroviral therapy (ART) 
 
The secondary outcomes will 
compare between arms the 
following endpoints occurring 
within 56 days of randomisation:  
 
2.1 time to all-cause mortality 
 
2.2 proportions of patients with (a) 
a microbiologically confirmed 
diagnosis of TB and (b) 
clinically diagnosed TB 
disease 
 
 
2.3 time from randomisation to (a) 
TB diagnosis and (b) start of 
TB treatment in days 
 
2.4 proportion of patients receiving 
(a) antibacterial treatment (b) 
in ART naïve patients, 
proportion starting ART and 
time to ART initiation in days 
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2.5 other clinically relevant 
outcomes, including (a) 
duration of hospital 
admission, (b) the need for 
hospital readmission and (c) 
loss to follow-up. 
 
 
2.5 (a) duration of hospital stay in 
days (b) cumulative incidence 
of hospital readmission (c) 
cumulative incidence of loss to 
follow-up. 
 
3. Economic 
Analysis  
3.1 to determine the incremental 
cost-effectiveness of high 
sensitivity urine-based TB 
screening in HIV-infected 
medical in-patients in South 
Africa (a middle-income 
country) and Malawi (a low-
income country). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 to determine the 2-year and 
5-year budgetary impact of 
implementation and scale-up 
of this intervention from a 
Ministry of Health perspective 
for both South Africa and 
Malawi. 
3.1 economic analysis will require 
measurement of trial-related 
efficacy endpoints in addition 
to data on: 
(a) length of hospital stay and 
subsequent healthcare 
utilisation 
(b) hospital resource utilisation 
(eg drugs administered, 
investigations undertaken, 
procedures undertaken)  
(c) hospital resource costs (eg 
drug costs, investigations, 
laboratory costs, 
hospitalisation costs) 
(d) patient quality of life data 
 
These will be modelled and 
compared between current 
standard of care for TB 
detection and intensified TB 
screening protocol which 
includes urine-based TB 
screening. 
 
3.2 outcomes, data from 
economic analysis and data on 
local and national Ministry of 
Health budgets. 
Investigational Trial 
Intervention(s) 
Testing of urine using:  
(a) Determine TB-LAM (Alere, Walthem, MA, USA; a rapid lateral-
flow assay), 
(b) Xpert MTB/RIF (Cepheid Inc, Sunnyvale, CA, USA) following 
concentration of urine by centrifugation.  
 
Results will be provided to the responsible medical team as soon as 
available to inform decisions regarding TB treatment (intervention 
arm only). 
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3. ABBREVIATIONS 
 
AIDS Acquired Immune Deficiency Syndrome 
ART Antiretroviral Therapy 
BMI Body Mass Index  
CI Chief Investigator 
CRF Case Report Form  
CRP C-reactive Protein 
CTRG Clinical Trials and Research Governance 
CXR Chest X-Ray 
DMC/DSMB Data Monitoring Committee / Data Safety and Monitoring Board 
FBC Full Blood Count 
GCP Good Clinical Practice 
HIV Human Immunodeficiency Virus 
ICF Informed Consent Form 
ICH International Conference of Harmonisation 
IRB Independent Review Board 
IUATLD International Union Against Tuberculosis and Lung Disease 
LAM Lipoarabinomannan 
LSHTM London School of Hygiene & Tropical Medicine  
LTFU Loss to follow-up 
MLW Malawi-Liverpool-Wellcome Trust Centre 
PI Principal Investigator 
PITC Provider initiated testing and counselling 
REC Research Ethics Committee 
PLHIV People living with HIV infection 
SAE Severe Adverse Event 
SAR  Severe Adverse reaction 
SFTP Secure File Transfer Protocol 
SOP Standard Operating Procedure 
SUSAR Suspected Unexpected Serious Adverse Reactions 
TB Tuberculosis 
WHO World Health Organisation 
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4. BACKGROUND AND RATIONALE 
4.1. HIV-associated tuberculosis (TB) 
 
Burden of disease: Tuberculosis (TB) and TB/HIV co-infection remain enormous challenges 
to international public health even in regions with high coverage of ART. The HIV/AIDS 
epidemic has had a particularly devastating impact on TB control in sub-Saharan Africa which 
accounts for 78% of the global burden of HIV-associated TB and a majority of the resulting 
360,000 deaths each year [1]. The countries of southern Africa are hardest hit and here more 
than half of TB patients are HIV co-infected. TB is the leading cause of death in people dying 
with HIV/AIDS [2]. This high mortality burden has become a high-level strategic priority with 
calls spurring for action from WHO, UNAIDS, STOP TB, PEPFAR and other agencies. 
Current failure of diagnosis: Post-mortem studies of patients with HIV/AIDS dying in 
hospitals in countries in west, east and southern Africa uniformly report that between 32% 
and 64% of cadavers have evidence of TB (mostly disseminated) [3–7] even in patients 
receiving ART [3,4]. Multi-drug resistant disease is another important factor in South Africa 
[3,8]. Much of the TB found in these post-mortem studies remained undiagnosed and 
unsuspected at the time of death, presenting a strong rationale for routine systematic TB 
screening of all HIV-infected admissions, irrespective of clinical presentation.  
We believe that mortality is fuelled by under-diagnosis, delays in diagnosis due to selective 
investigation of patients, overreliance on sputum-testing, inability to diagnose much 
extrapulmonary disease, lack of effective diagnostic tools, weak laboratory infrastructure and 
failure to screen for rifampicin resistance. Recent key developments in the field of TB 
diagnostics provide new opportunities to address these deficiencies. Based on the CI’s recent 
studies in Cape Town, South Africa, this study will evaluate a fundamentally new, rapid, high 
sensitivity approach to screening for HIV-associated TB in HIV-infected medical in-patients 
using urine-based diagnostics [9]. 
New diagnostic tools: The Xpert MTB/RIF rapid molecular assay has been endorsed by 
WHO for diagnosis of HIV-associated pulmonary TB and rifampicin resistance using sputum 
and it is being implemented in many African countries [6]. An increasing evidence base 
shows good diagnostic accuracy when testing a wide range of extrapulmonary samples 
[10,11]. Of note, assay specificity has been uniformly high (approximately 98%) regardless of 
sample type tested [10,11], indicating that the test can reliably be used on non-respiratory 
samples as a rule-in test to inform TB treatment decisions. In 2014, the WHO released 
guidelines for the use of Xpert to test non-respiratory samples for diagnosis of EPTB [12,13]. 
Studies (including those of the CI) have reported useful diagnostic accuracy when used to 
screen urine samples from HIV-infected inpatients and out-patients [9,14,15]. 
The Determine TB-LAM assay is a simple lateral-flow (strip-test) antigen detection assay for 
urine lipoarabinomannan (LAM) that is now commercially available [16–18]. It can be used to 
diagnose TB within 30 minutes. In the most comprehensive assessment of specificity to date 
among in-patients in South Africa, specificity exceeded 99%, indicating that the test can 
reliably be used as a rule-in test to inform TB treatment decisions [9]. 
Relevant systematic reviews: One systematic review and three comprehensive narrative 
reviews summarize the current state of urine-based TB diagnosis. No studies have yet 
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reported on the impact of urine-based diagnostics on clinical outcomes when used for 
routine, systematic TB screening of HIV-infected hospital in-patients. 
 
 Peter J. et al. Urine for the diagnosis of tuberculosis: current approaches, clinical 
applicability, and new developments. Curr Opin Pulm Med 2010 May; 16(3):262-70. 
[19] 
 Minion J. et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic 
review and meta-analysis. Eur Respir J 2011 Dec; 38(6):1398-405. [20] 
 Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis 
of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012 Apr 26; 
12(1):103. [16] 
 Lawn SD, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and 
future prospects for a point-of-care test. Lancet Infect Dis 2013 Apr; 13(4):349-61. [21] 
Please see appendix F for a summary of diagnostic accuracy of Xpert MTB/RIF and 
Determine TB LAM assays. 
4.2. Study Rationale 
 
Background studies informing the study intervention: Background studies 
conducted by the CI in South Africa (see Figure 1 below and ref [9]) have demonstrated that: 
 
 The overall prevalence of TB (defined using comprehensive microbiological sampling and 
investigation) among unselected HIV-infected medical in-patients at the time of hospital 
admission was very high (33% overall; 40% in ART-naïve patients; 27% in those on ART).  
Symptoms were neither sufficiently sensitive nor sufficiently specific to be a useful 
component of TB screening strategies applied to this patient group.  
 
 The diagnostic yield from testing sputum samples with Xpert MTB/RIF in the initial 
diagnostic screen was low, at 27% of the total microbiological diagnoses (Figure). This, in 
part, reflects the difficulty in obtaining sputum samples from debilitated in-patients: only 
one half of patients screened were able to produce a sputum sample during their total in-
patient stay. Of all patients with a confirmed diagnosis of TB, just 54% had microbiological 
evidence of TB from respiratory samples compared to 83% from non-respiratory samples 
(P<0.001). 
 
 In contrast, urine samples were obtained from almost all patients screened and yielded a 
majority (69%) of total TB diagnoses. Rapid urine testing using Determine TB-LAM lateral-
flow test for lipoarabinomannan (LAM) antigen had high specificity (98.9%) and provided 
results within 30 minutes using a 60µL aliquot of unprocessed urine. A second urine test 
used a 40 ml urine sample which was first concentrated by centrifugation and then tested 
using the semi-automated rapid molecular assay, Xpert MTB/RIF, providing results within 
2 hours. Xpert MTB/RIF testing of concentrated urine provided the greatest yield (59%) of 
any single test, and the yield was further increased when combined with other tests. The 
comparative yields of sputum- and urine-based tests are outlined in Figure 1. 
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 Use of these rapid assays on both sputum and urine samples obtained in the first 24 hours 
rapidly diagnosed a large majority (81%) of total microbiologically confirmed TB disease 
(Figure 1). 
 
 Urine-based testing also diagnoses TB in patients with the highest mortality risk [14,22], 
thus rapidly identifying those who have most potential gain from rapid initiation of TB 
treatment. 
 
  
Figure 1. Data from background study in Cape Town showing the comparative 
diagnostic yield of sputum-based, urine-based and combined approaches in unselected 
HIV+ medical in-patients. The reference standard was a composite of total 
microbiologically confirmed TB following intensive investigation [9]) 
 
The need for studies of clinical impact: Although the use of urine-based screening for TB 
increases the sensitivity of TB diagnosis in this clinical population, there is no evidence that 
urine-based testing will have any impact on clinical outcomes.  
Replacement of sputum smear microscopy with sputum Xpert MTB/RIF has not been found 
to improve clinical outcomes when investigating patients suspected of having TB [23–27]. 
This may be due to high rates of empirical TB treatment which may be increased as a result 
of changes in prescribing behaviour in studies with unblinded study design [25–27].  
However, a critical difference in the design of the present study is the strategy of investigating 
ALL patients regardless of whether TB is suspected or not: post-mortem studies and 
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background data from Cape Town [9] show that a huge burden of TB remains clinically 
unsuspected and is not empirically treated. Moreover this study uses masking of clinical 
teams, thereby reducing the risk that empirical TB treatment or changes in prescribing 
practice during the trial will undermine this study [28]. 
Update 5th February 2016: The LAMRCT trial released its results in December 2015.[Abstract 
41. The Union/CDC Late-Breaker Session on TB, 46th Conference of the International Union 
against Tuberculosis and Lung Disease, Cape Town, December 2015] It randomised adult, 
HIV-positive hospitalised patients ‘with TB symptoms’ to either ‘routine diagnostics’ or ‘routine 
diagnostics plus adjunctive urine LAM testing’. The study was conducted at 4 sites in sub-
Saharan Africa (South Africa, Zimbabwe, Zambia and Tanzania).  The primary outcome was 
mortality at 8 weeks, and the trial reported a 4% reduction in mortality in the urine LAM arm 
(20.8% mortality in no LAM arm, compared to 24.9% mortality in the LAM arm). [Peters J, 
Zijenah LS , Chanda D et al, The mortality impact of point-of-care urine lipoarabinomannan 
testing to guide tuberculosis treatment initiation in HIV-infected hospitalised patients: a multi-
country randomised controlled trial. The Lancet 2016, In press] 
Potential harms from screening: High diagnostic sensitivity alone does not justify the 
implementation of urine-based diagnosis. Rapid TB diagnosis might benefit this clinical 
population, but there is no evidence demonstrating that this is the case. Urine-based testing 
could be associated with a range of adverse consequences. These include the following: 
 
 Rapid TB diagnosis may reduce the likelihood that patients receive an empirical course of 
simple antibiotics as part of the diagnostic work-up such that concurrent sepsis is not 
treated and may divert clinical attention from the presence of other co-pathologies. 
 As with most diagnostic assays, the specificity of these urine-based approaches to 
diagnosis is unlikely to be consistently 100%, giving rise to the potential for some false-
positives. 
 Use of Xpert MTB/RIF to test urine samples may be associated with false-positive 
rifampicin resistance results in some patients. In populations with low prevalence of 
MDRTB, the positive predictive value of this result is low and may lead to the inappropriate 
use of more toxic and expensive MDR-TB treatment. 
 If this strategy were adopted as policy, use of limited health service resources for 
purchasing costly diagnostics may divert resources from other important health system / 
programmatic needs which may have greater impact on health. 
 
In the presence of unproven benefits but also the potential risk for harm (both individual and 
programmatic), a randomised controlled trial is essential to assess overall clinical impact and 
cost-effectiveness to provide the essential evidence base to formulate policy. 
 
Generalisability of research: Autopsy studies of HIV-infected in-patients conducted across 
different regions of Africa (west, east and southern) and in India [3–7], show that 
undiagnosed TB is common in all settings. This study will build on the CI’s previous work in 
Cape Town by including a new site in South Africa, and a site in Malawi (a resource-limited 
setting) with an anticipated lower prior probability of TB than South Africa. This will ensure the 
results of this trial will be broadly generalisable to other HIV-infected medical in-patient 
populations across sub-Saharan Africa, and also in other resource-limited settings with a high 
burden of TB. However, the results should not be generalised to HIV-infected medical out-
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patients in whom the frequency of disseminated disease and renal involvement with TB is 
likely to be lower. 
4.3. Principal Research Question 
 
Does implementation of a novel, rapid, high sensitivity urine-based screening strategy for TB, 
used in combination with routine sputum-based standard of care diagnosis, reduce all-cause 
mortality among HIV-infected medical in-patients newly admitted to hospitals in southern 
African countries?  
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5. OBJECTIVES AND OUTCOME MEASURES / END-POINTS 
 
Objectives Outcome Measures/Endpoints  
 
1. Primary Objective 
To determine whether the addition of rapid, 
high sensitivity urine-based TB screening to 
the diagnostic standard of care for HIV-
infected patients requiring admission to 
medical wards in hospitals in southern Africa 
reduces all-cause mortality 
 
 
Risk of death at 56 days after randomisation 
from any cause, compared between arms. 
 
 
2. Secondary Objectives  
To determine the impact of additional urine-
based TB screening versus standard of care 
on: 
2.1 time to death from any cause 
 
2.2 the yield of TB diagnoses that are (a) 
microbiologically confirmed disease or 
(b) clinically diagnosed disease (see 
definitions in section 8.6) 
 
2.3 time to (a) TB diagnosis, (b) start of TB 
treatment and (c) time between TB 
diagnosis and start of TB treatment (see 
definitions in section 8.6)  
 
2.4 use of other medical interventions, 
including (a) antibacterial medication (b) 
antiretroviral therapy (ART) 
 
 
2.5 other clinically relevant outcomes, 
including (a) duration of hospital 
admission, (b) the need for hospital 
readmission and (c) loss to follow-up. 
 
 
 
The secondary outcomes will compare 
between arms the following endpoints 
occurring within 56 days of randomisation:  
2.1 time to all-cause mortality 
 
2.2 proportions of patients with (a) a 
microbiologically confirmed diagnosis of 
TB and (b) clinically diagnosed TB 
disease 
 
2.3 time from randomisation to (a) TB 
diagnosis, (b) start of TB treatment in 
days and (c) time between TB diagnosis 
and start of TB treatment 
 
2.4 proportion of patients receiving (a) 
antibacterial medication (b) in ART 
naïve patients, proportion starting ART 
and time to ART initiation in days 
 
2.5 (a) duration of hospital stay in days, (b) 
cumulative incidence of hospital 
readmission, and (c) cumulative 
incidence of loss to follow-up. 
 
 
3. Economic Analysis Objectives 
3.1 to determine the incremental cost-
effectiveness of high sensitivity urine-based 
TB screening in HIV-infected medical 
in-patients in South Africa (a middle-income 
country) and Malawi (a low-income country). 
 
 
3.1 economic analysis will require 
measurement of trial-related efficacy 
endpoints in addition to data on: 
(a) length of hospital stay and subsequent 
healthcare utilisation 
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3.2 to determine the 2-year and 5-year 
budgetary impact of implementation and 
scale-up of this intervention from a Ministry 
of Health perspective for both South Africa 
and Malawi. 
(b) hospital resource utilisation (eg drugs 
administered, investigations undertaken, 
procedures undertaken)  
(c) hospital resource costs (eg drug costs, 
investigations, laboratory costs, 
hospitalisation costs) 
(d) patient quality of life data 
These will be modelled and compared 
between current standard of care for TB 
detection and intensified TB screening 
protocol which includes urine-based TB 
screening. 
3.2 outcomes, data from economic analysis 
and data on local and national Ministry of 
Health budgets. 
  
 STAMP protocol version 1.6 30/JAN/2018 
CONFIDENTIAL  Page 15 of 62 
6. TRIAL DESIGN 
 
A pragmatic, multi-country (Malawi and South Africa), individually randomized, clinical trial 
with two study arms (1:1 recruitment). Patients, research nurses, investigator team and the 
responsible medical team (other than trial statistician and laboratory technicians) will be 
masked to the randomised screening allocation. Patients randomised to the standard of care 
arm will be screened by testing sputum with Xpert MTB/RIF. Those in the intervention arm 
will, in addition to standard of care sputum testing, undergo rapid urine-based screening with 
Determine TB-LAM lateral flow assay and Xpert MTB/RIF assay testing of 40 ml urine 
following concentration by centrifugation. Laboratory-based diagnoses of TB will be 
communicated to the responsible medical team to inform TB treatment (while maintaining 
masking to screening arm allocation), but the clinical management by the medical team will 
not be altered. Outcomes will be compared between arms 56 days after randomisation. 
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Figure 2. Trial flow chart  
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7. PARTICIPANT IDENTIFICATION 
7.1. Trial Participants  
 
People (aged ≥18 years) living with HIV infection (PLHIV) who require acute admission to 
hospital medical wards and who are willing and able to provide informed consent will be 
enrolled, regardless of clinical presentation and whether or not TB is clinically suspected, to 
the following clinical trial sites: 
 Zomba Central Hospital, Zomba, Malawi  
 Edendale Regional Hospital, Edendale, Pietermaritzburg, KwaZulu-Natal, South Africa 
7.2. Inclusion Criteria 
 
All medical admissions will be screened for eligibility, regardless of the admitting complaint. 
 
 Requires acute admission to a hospital medical ward at either clinical trial site for any 
reason 
 Have confirmed HIV-infection (existing or new diagnosis, irrespective of ART status) 
 Willing and able to provide informed consent 
 
7.3. Exclusion Criteria 
 
 Aged <18 years 
 Has been admitted to a medical ward for longer than 48 hours 
 Has received treatment for TB within the preceding 12 months, or has received isoniazid 
preventative therapy (IPT) within the last 6 months 
 Residence does not lie within a pre-defined geographic area (with regard to the feasibility 
of follow-up) or plans to leave this area during the period of trial follow-up. 
 Unable or unwilling to provide informed consent 
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8. TRIAL PROCEDURES 
8.1. Recruitment 
 
All adult PLHIV (either a known diagnosis or a new diagnosis) referred for admission to 
medical wards (irrespective of clinical presentation and the reason for medical admission) will 
be referred by health service staff, with the patient’s prior agreement, for explanation of the 
study and assessment of eligibility. All adult patients who are not known to be HIV-infected 
are offered HIV testing (provider-initiated testing and counselling) on admission as standard 
clinical practice at both study sites. 
8.2. Screening and Eligibility Assessment 
 
Potential participants will be approached by the study team and informed about the study.  
Those willing to be screened for eligibility will be assigned a screening ID number and 
assessed by the study team as per the above criteria. A recruitment log will be kept of all 
potentially eligible patients admitted to each study site and screened patients who either are 
or are not enrolled, including the reasons for not being enrolled when available. 
If patients are HIV-positive, confirmation will be sought either in the form of confirmatory 
documentation (eg health passport or viral load results) or confirmatory HIV testing offered by 
the study team. Participants who meet all criteria but do not know their HIV-status will be 
offered rapid HIV testing by the study team. HIV testing will be undertaken by the recruiting 
study nurse who will be fully trained in local provider-initiated testing and counselling (PITC) 
practices, and using a locally approved HIV rapid testing algorithm. Results will be provided 
to the patient with appropriate counselling, and to responsible medical team for ongoing 
management, irrespective of whether the patient enrols in the trial. 
8.3. Informed Consent 
 
Written informed consent will be sought from participants before any trial-specific procedures 
are undertaken at screening, with witnessed thumbprint used for patients unable to read 
and/or write. A copy of the signed informed consent will be given to the participant. The 
assistance of a translator will be used where necessary and all patient information sheets and 
consent forms will be translated in to local languages. It will be clearly stated that the 
participant is free to withdraw from the trial at any time for any reason without prejudice to 
future care, and with no obligation to give the reason for withdrawal. 
 
8.4. Baseline Assessments and Procedures 
 
Following enrolment the study team will be responsible for obtaining, where possible: 
 one sputum specimen (spontaneously expectorated; no induction of sputum will be done 
unless this is standard of care at the trial site at the time of the study) to be tested using 
the Xpert MTB/RIF assay (if patients are unable to produce a sputum sample initially, they 
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will be instructed on how to do so and left with a sputum specimen container- one further 
attempt to obtain sputum will also be made by the study team within 4-6 hours). Patients 
who are not able to produce a sputum sample during this time will remain in the study but, 
thereafter, no further sputum TB investigations will be arranged by the study team, 
although the responsible clinical team will remain at liberty to arrange further TB tests as 
appropriate. 
 
 a urine specimen of >50 mls to be tested using the (i) Determine TB-LAM and (ii) Xpert 
MTB/RIF assays (testing will only be done on samples obtained from participants 
randomized to the intervention arm). 
15-20 mls of blood will be taken for the following tests: 
 CD4 cell count 
 Haemoglobin 
 C-reactive protein (CRP) 
 Serum save 
The study team will also collect information on: 
 Mobile phone numbers of the patient and/or designated relatives/next-of-kin 
 Demographic information including precise geographic/home locator information (to aid 
follow-up) 
 Clinical history including past history of TB treatment, HIV care, ART duration and 
regimen, and other illnesses such as opportunistic infections 
 Vital signs (including danger signs) 
 TB symptoms (including the WHO symptom screen) 
 Height and weight (to calculate BMI) 
 Mid-upper arm circumference 
 Quality of life questionnaire (EQ5-D) 
 Karnofsky score 
8.5. Randomisation procedure 
  
A randomisation list stratified by study site will be generated in advance by the study 
statistician with random block size to ensure equal numbers of participants are enrolled into 
each arm and each study site. Paper slips with randomisation number will be printed and 
inserted into envelopes for each site. The envelopes will be held by the study coordinator at 
each site and distributed to the nurse on enrolment of a participant. The randomisation 
number will act as unique study ID number. The envelope will not contain the intervention 
allocation. 
The study laboratory will be provided with a list of randomisation numbers and their study arm 
allocation. When samples from enrolled patients arrive at the laboratory, the TB tests to be 
carried out will be identified by checking the randomisation number with the list of study arm 
allocation. Sputum samples from all patients will be tested using the Xpert MTB/RIF assay, 
but only urine samples from patients allocated to the intervention arm will be tested using 
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rapid diagnostic tests. Code-breaking will not be required for this study given the nature of the 
intervention. 
The study team (other than trial statisticians and laboratory technicians) and the routine 
clinical team responsible for the patient will be masked as to study arm allocation. Unblinding 
of randomisation is not required, as treatment is not given as part of the study intervention (it 
is the responsibility of the routine clinical team) and all study results are issued to the routine 
clinical team.  
If patients are deemed to have an SAE related to TB treatment, treatment will simply be 
stopped at the discretion of the responsible clinical team. Any rare occasion where the clinical 
team consider that unblinding is necessary will it be considered by members of the trial 
steering committee on a case by case basis. 
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Figure 3. Flow chart of early trial procedures 
8.6.  TB Definitions  
 
TB events will be defined as follows for the purpose of this study: 
 
Microbiological diagnosis of TB (based both on study samples and on any samples requested 
by the routine medical team) will have at least one smear-microscopy, Xpert and/or culture 
positive result(s) on any specimen OR a positive urine Determine TB-LAM result. 
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Clinical diagnosis of TB will have a compatible clinical illness or radiological disease and/or 
the decision of the responsible clinical team to commence TB treatment in the absence of 
any positive microbiological tests for TB. 
Date of TB diagnosis for microbiological TB diagnoses this will be the date when the positive 
microbiological test result for TB was communicated to the responsible medical team (eg 
written in the hospital record), and for clinical diagnoses it will be the date of commencement 
of TB treatment. Date of commencement of TB treatment will be the first date that anti-TB 
medication was prescribed. 
8.7. Training for responsible medical team 
 
In addition to extensive training in the trial protocols and procedures, staff responsible for the 
routine delivery of care for patients in this trial will be educated with regards to the TB 
diagnostic tests being trialled. This will include information about the sensitivity and specificity 
of the individual tests and estimated setting-specific positive and negative predictive values 
for TB diagnosis and detection of rifampicin resistance, allowing them to make informed 
decisions on how to interpret test results. 
8.8. Subsequent procedures 
 
TB specimens and results (see figure 3): Samples will be immediately submitted to the 
hospital laboratory. The study nurse and responsible medical team (independent from the 
study team) will remain blinded to subsequent randomisation. In the laboratory, patients will 
have TB specimens tested according to whether randomised to the intervention or standard-
of-care arms.  
For both standard and intervention arms, Xpert MTB/RIF testing will be carried out on a 
single sputum sample where available. In the intervention arm only, urine will be tested using: 
(i) Determine TB-LAM and (ii) 40 ml urine will be concentrated by centrifugation and the pellet 
tested using Xpert MTB/RIF. 
If there is an error or “indeterminate” result with the Xpert MTB/RIF assay, the test will be 
repeated on the same sample if possible (as per local and WHO guidelines). If an Xpert 
MTB/RIF test reports an isolate as rifampicin resistant, the test will be repeated as per local 
and WHO guidelines.[12,13] Similarly, if the Xpert MTB/RIF test gives an inconclusive 
rifampicin resistance result, the test will be repeated.[12,13] 
Results of TB tests will be issued as soon as available and communicated to the responsible 
medical team to inform decisions regarding TB treatment (anticipated to be within 24-48 
hours). These will be issued as “positive test for TB” or “negative test for TB” without 
specifying sample type so as to maintain masking of the responsible medical team. The 
results of Xpert MTB/RIF testing for genotypic rifampicin resistance will also be provided as 
either “no rifampicin resistance mutations detected” or “rifampicin resistance mutations 
detected”. Discordant rifampicin resistance results will be managed as per local and WHO 
guidance.[12,13] If only the urine TB-LAM assay is positive, no rifampicin resistance results 
will be issued to the medical team. If no samples are provided to the study team for TB 
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testing, or submitted samples are unable to be tested for any reason, it will be communicated 
to the responsible medical team that “no [trial] TB test results are available”. 
The routine investigation and management of patients according to local protocols will not 
otherwise be altered. Participation in the trial will not prevent the responsible medical team 
from requesting additional TB tests if clinically indicated. However, the study team will not be 
involved in the collection or processing of any such additional TB tests. 
In addition to TB test results, CD4 cell count and haemoglobin results will be provided to the 
responsible medical team as soon as they are available for patients in both study arms. 
 
Follow-up during hospital admission: Following the initial TB screen, the study team will 
have no role in routine patient investigation, care and management.   
Patients will remain under the care of their responsible medical teams who will be responsible 
for all clinical decisions including initiation of TB treatment, ART, co-trimoxazole prophylaxis 
and treatment for co-morbidities according to local and national guidelines. The research 
team will supply the results of TB screening assays and CD4 cell counts, but will otherwise 
have no role in medical management. 
However, the study team will extract records of all medical interventions received and clinical 
outcomes during the hospital admission by regular review of clinical records and/or 
discussion with medical team. Information will be collected about key medical interventions 
and clinical events, including: 
 Timing of study TB test report 
 Any further TB tests, including nature of specimens and results 
 TB diagnosis, including date of diagnosis 
 Commencement of TB treatment, date of starting treatment, reasons for commencement 
(e.g. microbiological results, chest x-ray or clinical symptoms in the absence of positive 
microbiological tests) 
 Initiation or administration of ART, including regimen and timing 
 Initiation or administration of co-trimoxazole therapy 
 Initiation of isoniazid preventative therapy 
 Concomitant bacterial infection or prescription of antimicrobials (other than TB treatment) 
 Other opportunistic infections based on tests or treatment given 
 Vital status, including time of death 
 Time to discharge and length of hospital stay 
 Side-effects of TB treatment  
 Serious or severe adverse events (see section 9) 
 
Storage of specimens: Urine samples from patients in both study arms will be stored for up 
to 5 years. These will be tested with repeat urine TB LAM assays, Xpert MTB/RIF assay and 
other antigen capture and/or nucleic acid amplification tests that have been developed in the 
interim for retrospective case verification and test diagnostic accuracy of new TB diagnostics. 
The stored urine samples will also be used to investigate options for pre-treatment of urine 
that could potentially increase the sensitivity of antigen capture diagnostic tests such as TB-
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LAM. Repeat testing of urine from patients who test positive with urine TB LAM but negative 
with Xpert MTB/RIF will also be useful to further understand this patient population. 
Similarly, 2-5ml of serum from all patients will also be stored for up to 5 years. This will be 
used for batch testing for CRP, retrospective Cryptococcal antigen testing and immunological 
profiling in a supplementary nested case-control study exploring risk factors for mortality 
(sub-study planned for Malawi trial site only). The immunological tests will include testing 
functional killing (using mCherry labelled M.smegmatis) and measuring cytokine responses to 
help understand the mechanisms underpinning any associations between positive urine-
diagnostic tests and mortality. Serum will also tested with other serological, antigen capture 
and/or nucleic acid amplification tests that have been developed in the interim for 
retrospective case verification and testing diagnostic accuracy. 
8.9. Follow-up procedures and ascertainment of outcomes 
 
Patients enrolled in the study will have subsequent management and follow-up as arranged 
by the medical team responsible for their care (including HIV care and ART if eligible). In 
addition, all patients in the study will be followed-up by the study team at 56 days post-
randomisation, wherever possible by face-to-face interview. There will be a provision of 
finance to patients to cover time and local transport costs. During the single follow-up visit, 
the following information will be collected: 
 Vital status 
 TB investigations or diagnosis made since discharge, including timing of TB diagnosis and 
commencement on or discontinuation of TB treatment 
 For those patients in whom TB has been diagnosed, linkage to out-patient TB care, 
progress on TB treatment, TB-treatment related toxicity requiring discontinuation and/or 
change in course, details of TB clinic attendance, whether they have a supply of TB 
medication and adherence to treatment  
 Health-service use including number and type of clinic visits, new antimicrobials 
prescribed, site, duration and nature of any hospital admissions (patients will be asked to 
take note of this upon discharge) 
 For patients who have had a subsequent hospitalisation, hospital records will be reviewed 
to determine duration of hospitalization and diagnoses when possible 
 For patients who were diagnosed with TB during their hospital admission and were 
enrolled in the strain diversity sub-study (Edendale, South Africa site only), a further 
sputum and urine sample will be requested for mycobacterial culture 
In the event that a patient does not attend follow-up, contact will be made by mobile phone 
with the patient or their designated contact/relative/next-of-kin. Careful documentation during 
hospital admission of precise home location will also enable home visits to be made, when 
required, by dedicated community-based study team workers to collect follow-up outcome 
data. By these means, losses to follow-up will be minimized. Patients who cannot be 
contacted or traced by phone or home visits will be classified as lost to follow-up after three 
tracing attempts. Date last seen alive will also be ascertained from next-of-kin when possible. 
To minimize ascertainment bias, registers (eg ART registers, TB registers) and records will 
be reviewed for patients lost to follow-up to document vital status and secondary outcomes. 
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Patients will also be asked to provide informed consent to be contacted by telephone at 6 
months after enrolment to ascertain vital status, and/or for death registers to be searched 
using South African identification numbers to ascertain vital status at 6 months after 
enrolment (Edendale, South African site only). 6 month mortality will be ascertained for those 
patients that agree to this. 
8.10. Discontinuation/Withdrawal of Participants from Trial Treatment 
 
Each participant has the right to withdraw from the trial at any time.  In addition, the 
Investigator may discontinue a participant from the trial at any time if the Investigator 
considers it necessary for any reason including ineligibility (either arising during the trial or 
retrospectively having been overlooked at screening), significant protocol deviation or 
withdrawal of consent. The reason for withdrawal will be recorded in the CRF. 
8.11. Definition of End of Trial 
 
The trial will be considered closed following the completion of follow up of the last participant, 
and once all follow-up and laboratory reports have been received. The trial may be 
terminated early by the trial steering committee, data safety monitoring board, regulatory 
authorities or the funders, for example if interim analysis shows an unacceptably high 
mortality in the intervention arm, as defined in the analysis plan. 
8.12. Understanding risk-factors and mechanisms for mortality in patients with 
HIV-associated TB diagnosed by rapid urine-based tests: a sub-study 
(Zomba, Malawi site only) 
 
Studies performed by the CI in South Africa, as well as other urine LAM diagnostic accuracy 
studies, have demonstrated that hospitalised patients who have positive urine-based 
diagnostic tests (especially using the Determine TB-LAM lateral flow assay) have between 
two and four-times increased risk of early mortality, even after adjustment for CD4 cell count 
[9]. The exact mechanisms underlying this increased mortality risk compared to other patients 
with HIV-associated TB remain unclear. Possible causes of this association include: (i) 
positive urine-based diagnostic tests may simply be a marker for more severe, disseminated 
TB disease; or (ii) this effect may be due to high concentrations of LAM systemically, which 
itself has direct and profound immune-suppressive effects, undermining the host immune 
response to Mycobacterium tuberculosis and/or other opportunistic pathogens. 
Understanding the mechanisms behind this association may inform adjunctive inventions (for 
example immunomodulation, broad-spectrum antibiotics or greater intensity of supportive 
care) aimed at reducing the high mortality in this patient population. This is especially 
important if the STAMP trial demonstrates TB screening with rapid diagnostics alone are not 
enough to improve clinical outcomes, in which case adjunctive interventions will be vital. 
To address these questions, we will undertake a sub-study amongst participants enrolled in 
the STAMP trial to assess risk-factors for mortality and compare functional (innate and 
acquired) immune responses between those with and without positive urine-based diagnostic 
tests. We will enrol only those patients with microbiologically confirmed HIV-associated TB 
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(defined as any positive STAMP or non-STAMP related TB investigation including the TB-
LAM, Xpert MTB/RIF or mycobacterial culture). The anticipated sample size is 100 patients, 
although the sample size may be altered in response to initial results. 
Prior to commencement of TB therapy, potential participants enrolled in the STAMP trial will 
be informed of the sub-study and written informed consent will be sought from using 
standardised information sheets and consent forms (provided as a separate document). 
Following provision of informed consent and enrolment in the sub-study, a further blood 
sample of 5-10mls will be taken for functional killing immunological assays to be done entirely 
in vitro (using mCherry labelled Mycobacterium smegmatis) and intracellular cytokine staining 
assays to assess the innate and acquired immune system (these assays require a fresh 
whole blood sample).  
Serum/plasma levels of cytokines (markers of immune activation and anti- and pro-
inflammatory cytokines, including TNF-alpha, interferon-gamma, interleukin-6, interleukin-12, 
and interleukin-10 as well as sCD14 – a marker of macrophage activation) will be measured 
by enzyme-linked immunoassays using stored serum samples already taken upon enrolment 
to the STAMP trial. No other additional specimens or data will need be collected as part of 
this sub-study, only the existing data collected and stored for the STAMP study will be used. 
No additional samples taken for this sub-study will be stored, any blood that is taken but not 
used will be safely disposed of immediately. All immunological assays will be run in Malawi. 
This sub-study will comply with all other aspects of the STAMP study protocol with regard to 
the acquisition and storage of personal data and maintenance of patient confidentiality. None 
of the additional immunological parameters to be measured in the sub-study has any 
immediate medical significance that would warrant the patient or medical team to be 
informed. Thus, this sub-study will in no way alter patient management. 
In the analysis, median levels of cytokines will be compared between patients with and 
without positive urine-based TB diagnostic tests. Similar analyses will be performed 
comparing patients who die and those who survive. Associations between cytokine levels and 
mortality will also be assessed using linear regression. A similar approach will be employed 
to determine the impact of urine-based diagnostic test status on functional immune response 
and intracellular cytokine analysis. Logistic regression modelling will also be used to 
determine clinical and immunological risk factors for mortality, including positive urine-based 
TB diagnostic tests. 
8.13. Mycobacterium tuberculosis strain diversity among HIV-infected adults 
hospitalized in South Africa: pilot cohort sub-study (Edendale, South Africa 
site only) 
 
Background and research questions 
Sub-Saharan Africa (SSA) accounts for almost 80% of the global tuberculosis (TB) burden, 
and most of the 400 000 TB deaths each year [1].   Mortality due to TB remains the leading 
cause of death in HIV-infected patients despite of increasing coverage of ART and rollout of a 
new nucleic amplification diagnostic test [1].  Studies from various geographical settings have 
reported on the ability of individuals with active TB to simultaneously harbour a diverse range 
of distinct Mycobacterium tuberculosis (MTB) strains. Strain diversity, or within-host 
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heterogeneity alludes to ‘complex MTB infections’ that arise through either multiple infection 
events or within-host mutations [29]. In a recent outpatient in the Edendale Hospital 
catchment area investigating within-host heterogeneity among 500 outpatients initiated on TB 
treatment, 21.1% of patient had evidence of harbouring mixed MTB infections at treatment 
initiation; which was also associated with increased failure to culture convert at 8 weeks after 
treatment initiation (adjusted OR 1.90; 95% CI, 1.03-3.50) [29]. In addition, recent post-
mortem studies at Edendale Hospital using new whole genome sequencing (WGS) 
techniques have shown that mixed MTB infections not only move from one lung site to 
another, but also to disseminate to extrapulmonary sites [30].  
In life, most body compartments cannot be easily sampled to detect MTB stain diversity. 
However, recent work suggests that urine-based TB diagnostics may offer additional 
diagnostic yield to more conventional sputum based tests, offering the opportunity to 
compare MTB strain diversity in the respiratory and renal compartments [31,32]. Yet, it is not 
known what the implications would be of strain diversity detected on WGS in these 
compartments, for example on culture conversion in hospitalized adults with newly diagnosed 
TB. The understanding of such preferential compartmentalisation could inform alternative 
diagnostic and treatment strategies, and potentially impact HIV-associated TB mortality. To 
address these questions, we will undertake a pilot cohort sub-study (embedded in the 
STAMP trial) amongst all patients proven to have microbiologically confirmed HIV-associated 
TB on Xpert MTB/RIF and/or urine Determine TB-LAM at Edendale Hospital in order to: 
 
1. Determine what is the prevalence of complex MTB infections among HIV-positive 
individuals hospitalized in a regional hospital KwaZulu Natal  
2. Determine whether TB strains show diversity between sputum and urine compartments in 
hospitalized HIV-infected individuals  
3. Explore associations between mixed MTB infections and clinical outcomes (including 
culture conversion) at 8 weeks after treatment initiation   
 
Study design 
We will obtain written informed consent from all patients enrolled in the STAMP trial to get 
extra samples, at two time points, of (a) sputum (3ml) and (b) urine (40 ml) from all those who 
are diagnosed with tuberculosis during hospital admission in the STAMP study (either based 
on STAMP study TB investigations or routine hospital TB investigations). These samples will 
be taken directly after the diagnosis of TB (this will not delay TB treatment initiation) and at 
56-day follow up. All samples will be immediately and securely transported to the KwaZulu 
Natal Research Institute for TB and HIV (K-RITH), Durban, KZN. Here, specimens will be 
pooled and grown in liquid culture medium (BACTEC MGIT 960; Becton-Dickinson, NJ). 
Positive cultures will be identified by the niacin-nitrate test. Mycobacterial DNA will then be 
extracted from the liquid medium from all positive cultures and be batched processed and 
analyzed for strain diversity/heterogeneity using next generation whole genome sequencing 
(WGS) [33]. The results will not be reported to patients or medical teams unless drug 
resistance genes are identified. WGS results will not be available within the 56-day follow up 
period and therefore will not impact or alter the STAMP study design.  
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Definitive mixed strain/complex infection will be defined by the presence of more than one 
allele at more than one MIRU-VNTR locus and as definite clonal population infections when 
more than one allele at a single locus will be present. In depth bio-informatics analysis will be 
done to identify strain diversity within (i.e. sputum compartment) and between anatomical 
sites (i.e. urinary and sputum compartments). Analysis will also be undertaken to calculate (a) 
the prevalence of complex infection overall and amongst urinary and sputum compartments 
at baseline. The results of MTB WGS testing will not be clinically meaningful and therefore 
will not be reported to patients or medical teams.  
 
Sample Size 
Assuming that 20% of ‘STAMP” patients will be diagnosed with TB, 20% of the 800 
consecutive patients (n=160) to be recruited as part of the STAMP trial (as of from 1 August 
2016) will be included in the sample size for further genomic analysis. For an overall sample 
size of 160 and assuming the prevalence of mixed infections ranges from 10-20%, then the 
following table shows precision for estimates of prevalence of mixed infections and power for 
the exploratory objective of comparing culture conversion in the mixed infections and non-
mixed infection groups:  
 
Prevalence of mixed 
infection (number) 
95% CI  for prevalence Power assuming 30% culture convert in 
mixed infections group & 60% culture 
convert in non-mixed infections group 
10% (16) 5.8-15.7% 53% 
15% (24) 9.9-21.5% 72% 
20% (32) 14.1-27.0% 85% 
 
This sub study will comply with all other aspects of the STAMP trial protocol with regard to 
the acquisition and storage of personal data and maintenance of patient confidentiality. 
 
8.14. Ultrasonic evidence of extra-pulmonary TB using focused assessment 
with sonography for HIV/TB (FASH) in patients with HIV-associated TB 
diagnosed by rapid urine-based tests- a sub-study (Zomba, Malawi site 
only) 
 
Background information and introduction 
There is strong evidence to support that HIV-associated TB diagnosed by rapid urine-based 
tests is indicative of haematogenously disseminated renal TB.[34] The diagnosis of extra-
pulmonary TB (EPTB) remains challenging, especially in poorly resourced settings. However, 
ultrasonography can be used to aid diagnosis of EPTB through detection of characteristic 
features such as pleural effusions, pericardial effusions, abdominal lymph node and/or 
splenic micro abscesses.[35–37] A simple point-of-care ultrasound protocol for focused 
assessment with sonography for HIV/TB (FASH) has been developed and successfully used 
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to identify EPTB following training of non-radiologist health care workers in resource-limited 
settings.[38–41] 
 
Rationale/justification for the research project 
 
It remains unknown what proportion of patients diagnosed with HIV-TB who are admitted to 
hospital have ultrasonic evidence of EPTB using FASH, and whether this is more common in 
patients with positive rapid urine-based TB tests (and therefore have disseminated TB). It is 
also unknown what proportion of HIV-positive hospital in-patients with no evidence of TB 
have ultrasound signs suggestive of EPTB. Understanding the prevalence of these 
ultrasound changes can inform the use of FASH for identification of EPTB amongst HIV-
positive hospitalised patients. To address these questions we will undertake a sub-study 
amongst patients enrolled in the STAMP trial to describe the prevalence of ultrasonic 
evidence of EPTB using FASH.  
 
Objectives of the study 
 
1. To describe the prevalence of ultrasound evidence of EPTB using FASH amongst 
patients admitted to hospital with HIV-associated TB 
2. To compare the prevalence of EPTB using FASH between patients with and without 
positive urine-based diagnostic tests 
3. To describe the prevalence of ultrasound evidence of EPTB using FASH in HIV-positive 
patients with no microbiological or clinical evidence of TB disease 
 
Study Population 
 
To establish the prevalence of EPTB as described by FASH and sensitivity of FASH (based 
on microbiologically confirmed TB as the gold standard) we will recruit only those patients 
enrolled to the STAMP trial with HIV-associated TB who have been commenced on TB 
treatment (defined as any positive STAMP or non-STAMP related TB investigation including 
the TB-LAM, Xpert MTB/RIF mycobacterial culture or sputum smear microscopy or the 
decision to commence TB treatment by a clinician). Following diagnosis of HIV-associated 
TB, potential participants enrolled in the STAMP trial will be approached for enrolment in this 
sub-study. 
To establish the prevalence of ultrasound evidence of EPTB using FASH in HIV-positive 
patients with no microbiological or clinical evidence of TB disease we will recruit only those 
patients enrolled to the STAMP study that have negative microbiological tests for TB (STAMP 
or non-STAMP related TB investigations), have no clinical evidence of TB infection during the 
STAMP study follow-up. Potentially eligible patients will be approached for enrolment at their 
STAMP trial 56-day follow-up visit. 
 
Sample Size 
 
We aim to recruit all eligible patients enrolled in the STAMP trial for the remaining duration of 
the trial. If TB prevalence is 15-30% amongst hospitalised HIV-positive patients enrolled into 
the STAMP trial, we would expect to recruit between 105-210 patients in this sub-study. 
Assuming recruitment of 150 patients to this sub-study, and 50% prevalence of EPTB, we 
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would be able to report EPTB prevalence with an accuracy of +/-8% based on 95% 
confidence intervals. Assuming a prevalence of FASH abnormalities of 8%,[36] recruiting 100 
patients without HIV-TB would allow us to calculate the prevalence of FASH abnormalities 
with an accuracy of +/-5.3% based on 95% confidence intervals. 
 
 
Study Procedures, Data Collection and Analysis 
 
Following informed consent and enrolment in the sub-study, a focused assessment with 
sonography for HIV/TB (FASH) will be undertaken by a member of the STAMP study team 
(doctor or clinical officer) trained in FASH for the diagnosis of EPTB.[41] The ultrasound 
operator will be blinded to the STAMP study arm allocation, therefore will not know if the 
patient has a positive-urine test for TB. The FASH protocol will take fewer than 15 minutes, 
and can be done after initiation of TB treatment or those patients with TB disease. Results 
will be recorded as the presence or absence of pleural effusions, pericardial effusions, 
abdominal lymphadenopathy and splenic micro abscesses. Data will be recorded onto case 
report forms and also documented in the patients’ routine medical notes. Patients with at 
least one of: pleural effusions, pericardial effusions, abdominal lymphadenopathy and splenic 
micro abscesses will be defined as having evidence of EPTB using FASH. 
 
The study procedures during this study will in no way alter the main STAMP trial study 
intervention. 
 
Analysis will include the proportion of HIV-TB patients (any diagnosis) with ultrasonic 
evidence of EPTB using FASH and stratification by microbiologically confirmed TB disease 
and positive urine-based diagnostics. Sensitivity of FASH will also be calculated using 
microbiologically confirmed TB (defined as any positive STAMP or non-STAMP related TB 
investigation including TB-LAM, Xpert MTB/RIF mycobacterial culture or sputum smear 
microscopy) as the reference standard. Prevalence of EPTB using FASH will also be 
calculated amongst patients with no microbiological or clinical evidence of HIV-TB, and 
specificity will be calculated using a microbiological and clinical reference standard. This sub-
study will comply with all other aspects of the STAMP study protocol with regard to the 
acquisition and storage of personal data and maintenance of patient confidentiality. 
Findings will be presented to the department of medicine at Zomba Central Hospital and 
Queen Elizabeth Central Hospitals, to the National TB Programme at annual research 
dissemination meetings, and to the broader scientific community at relevant regional and 
international conferences. Findings will also be submitted for publication in relevant peer-
reviewed journals. 
     
Ethical Considerations 
 
All patients recruited into the STAMP study will have been informed of the sub-study and 
written informed consent sought using standardised information sheets and consent forms. 
The FASH protocol will take fewer than 15 minutes, and can be done after initiation of TB 
treatment, therefore it will not delay initiation of TB treatment or have any other potential risks 
or side-effects for participants. There will be no radiation exposure to patients or staff from 
ultrasound imaging. Any patients who have no microbiological or clinical evidence of TB but 
have signs of EPTB on FASH will be referred to HIV and/or TB clinics for further assessment 
and management as appropriate. 
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8.15. Determining the prevalence of virological failure in HIV+ patients 
admitted to hospital, and associations with mortality and TB (sub-study) 
 
Background 
 
Viral load measurement is recommended by the World Health Organisation (WHO) as the 
standard for monitoring treatment response in HIV infected patients on antiretroviral therapy 
(ART), and can help early detection of treatment failure and appropriate intervention. Routine 
viral load testing at 6 and 12 months after ART initiation and every 12 months thereafter is 
recommended by WHO to allow for early detection of treatment failure and appropriate 
intervention.[43] The third of UNAIDS 90-90-90 targets is to have 90% of all people receiving 
ART virologically suppressed by 2030. Barriers to meeting this target include how to 
implement viral load testing, as it is expensive, usually centralised and currently has long 
turnaround times between testing and issuing results.[44] Targeting patients suspected of 
having treatment failure due to clinical or immunological findings is one important aspect, for 
example those patients on ART who are admitted to hospital. 
The STAMP trial recruited unselected HIV+ patients admitted to hospitals, and noted 
substantially higher ART coverage in this population than previously reported (92.1% in 
Zomba, Malawi and 79.2% in Edendale, South Africa) with a median time on ART of 4.4 and 
3.4 years respectively. Despite this high ART coverage, median CD4 cell count was 
approximately 230 cells/mm3 at both sites, and mortality remained high. Virological failure 
due to poor adherence and/or the presence of HIV drug resistance is likely to be an important 
factor in this low CD4 cell count and high mortality despite good ART coverage. The 
prevalence of virological failure in this patient population is currently not known. However, this 
group may be an important target for rapid HIV viral load testing followed by adherence 
interventions and/or switching to second line therapy. 
Research questions 
 
1. What is the prevalence of unsuppressed HIV viral load in unselected HIV+ patients 
admitted to hospital on ART for ≥6months and enrolled in the STAMP trial? 
2. Is virological failure associated with mortality or TB in hospitalised HIV+ patients? 
3. What is the prevalence of genotypic drug resistance in hospitalised patients failing 
ART? 
 
 
 
Study design 
 
We will test HIV viral load in stored frozen plasma specimens from patients recruited to the 
STAMP trial who have been on ART for ≥6months will using quantitative reverse 
transcriptase polymerase chain reaction (RT-PCR). Laboratory logs and CRFs containing 
results of HIV RNA PCR tests will be stored securely in a locked cabinet. CRFs will entered 
into a secure, password protected database using optical character recognition software. 
Data on hospital stay and in-hospital and 56-day outcomes has already been collected as 
part of the STAMP trial. Unsuppressed viral load will be defined as ≥1000 copies/ml. The 
proportion of patients with unsuppressed viral load will be calculated, and assessed for 
association with TB and mortality using multivariable logistic regression. A sub-sample of 
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patients with unsuppressed viral load will undergo HIV genotyping to test for HIV drug 
resistance mutations and the proportion of patients with unsuppressed viral load who have 
genotypic drug resistance calculated.  
 
Ethical considerations 
 
Patients recruited to the STAMP trial who have provided plasma for storage have already 
provided written consent for the samples to be stored and tested later (within 5 years). Being 
a retrospective study, results may not be useful to alter clinical management of the patients 
from who the samples were obtained. However, if patients on ART for ≥6months are found to 
have detectable HIV virus ≥1000 copies/ml and known to be alive at the end of study follow-
up, we will attempt to contact them by telephone and recommend they have a review at their 
local ART clinic and/or communicate the results to HIV clinics or health facilities where 
patients were receiving their ART.  
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9. SAFETY REPORTING 
 
The main study-related procedures in this trial are systematic screening of hospitalised 
PLHIV for TB. In countries with generalised HIV epidemics, systematic symptoms-based 
screening for TB in PLHIV at each medical contact is internationally recommended standard 
of care, and part of national policy in both Malawi and South Africa. Because of the limited 
sensitivity of all available TB screening tools in PLHIV, there is no single recommended 
screening algorithm.   
Potential harms specifically attributable to the intervention arm of the trial, therefore, relate to 
the use of more intensive urine-based diagnostic tests. Unwarranted initiation of TB treatment 
as a result of a false-positive screening result is a potential concern (although evidence to 
date indicates high specificity of this screening approach).   
It will not, however, be possible to distinguish true-positive results from false-positive results 
on an individual basis, owing to the lack of a highly sensitive and specific gold-standard 
confirmatory test. Moreover, given the high mortality from undiagnosed TB in this patient 
group, combined with the high frequency with which empirical TB treatment is used, and the 
established good safety profile of standard tuberculosis treatment, the overall potential for 
harm to participants in the intervention arm is very low. 
Instead, risks will be minimised by: 
 Clearly communicating the limitations of all screening approaches and specifically relating 
to positive-predictive value of rifampicin resistance (Xpert MTB/RIF) to responsible 
medical teams through on-site training that will be repeated periodically.  
 Repeating the Xpert MTB/RIF before reporting any MTB isolate as rifampicin resistant (as 
per 2014 WHO recommendations)[12] 
 Conducting regular proficiency testing and quality assurance (QA) for the trial laboratories.  
As standard Serious Adverse Event (SAE) reporting will not be possible or appropriate for the 
reasons outlined above, the trial team will instead investigate and report periodically to the 
TSC, DSMB and Ethics Committees all events of: 
a) Death on TB treatment within 2 months of enrolment: the circumstances leading to 
decision by the clinical team to start TB treatment will be documented, including the results of 
screening tests allowing an excessive number of single-test positives to be identified 
promptly.    
b) Initiation of second-line TB treatment for suspected MDR TB  
All deaths (irrespective of cause) and readmissions to hospital will already be recorded and 
analysed as primary and secondary study outcomes. 
9.1. Definitions 
Standard definitions of serious adverse events as outlined by the ICH Guidelines for Good 
Clinical Practice are: 
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Serious Adverse Event (SAE): a serious adverse event is any untoward medical occurrence 
that: 
 results in death 
 is life-threatening (at risk of death at the time of the event, not an event that hypothetically 
may have caused death if event was more severe) 
 requires inpatient hospitalisation (regardless of length of stay, even if hospitalisation is a 
precautionary measure for observation, but excluding hospitalisation for pre-existing 
conditions) or prolongation of existing hospitalisation  
 results in persistent or significant disability/incapacity 
 ‘important medical events’ may also be considered serious if they jeopardise the 
participant or require an intervention to prevent one of the above consequences. 
9.2. Causality 
 
The relationship of each serious adverse event to the trial intervention will be determined by a 
medically qualified investigator, including causality, strength of the causal relationship and 
whether it was expected. Definitions are as follows: 
 Not related: the adverse event is probably produced by the participant’s clinical state or 
by other modes of therapy administered to the participant; there is no evidence of causal 
relationship with the trial intervention 
 Possibly related: there is some evidence to suggest a causal relationship with the trial 
intervention, for example a plausible temporal relationship, but other factors or therapies 
may explain the event. 
 Probably related: there is evidence to suggest a causal relationship, and more likely 
explained by the trial intervention than other factors or therapies 
 Definitely related: there is clear evidence to suggest a causal relationship, with no other 
possible contributing factors or therapies 
9.3. Procedures for Recording Serious Adverse Events 
 
Adverse events will be ascertained from: 
 patient medical records kept and reviewed during hospital admissions (including 
readmissions)   
 patient follow-up visit at 56 days post-randomisation, or reports from relatives/next-of-kin if 
patient cannot be contacted at follow-up 
The following information will be recorded in the CRF: description, date of onset, severity, 
assessment of relatedness to trial interventions, the circumstances leading to decision by the 
clinical team to start TB treatment/second line TB treatment (including the results of 
screening tests) and action taken. Only serious adverse events as described above and 
occurring during the study follow-up (56 days post-randomisation) will be recorded. SAEs will 
be recorded in CRFs and periodically reported to the DSMB and ethics committees. 
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9.4. Management of Serious Adverse Events 
 
Since all drugs used in this study are licensed drugs being used for licensed indications and 
being prescribed by the responsible clinical team, management of SAEs will be undertaken 
by the clinical team as per national and local guidelines and practice. As soon as the study 
team are aware of SAEs, as much information as possible will be documented in the CRF as 
per the relevant SOP. 
9.5. Data Safety Monitoring Board 
 
The Data Safety Monitoring Board (DSMB) will be responsible for independently reviewing 
study conduct, progress and interim findings, and making recommendations to the Trial 
Steering Committee (TSC), including any concerns that may warrant early termination of the 
trial. The DSMB will consist of at least 3 members, including an independent statistician and 
at least 2 clinicians, with at least 1 having clinical trials experience, and at least 1 having 
clinical expertise in the management of HIV and TB co-infection. The DSMB will receive 6-
monthly reports, including changes to protocols, study progress, enrolment statistics, SAEs 
and withdrawals. The DSMB will meet via teleconference following this report, and will 
provide written feedback to the PI/TSC. An interim analysis is planned and will be agreed 
upon with the DSMB before trial starts. 
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10.  ECONOMIC ANALYSIS 
 
Demonstrating the economic feasibility and cost-effectiveness of this rapid urine-based TB 
screening strategy, compared to the current standard of care, will be essential before policy 
implementation should it prove effective in reducing mortality or improving clinical outcomes. 
As this intervention is focussed at a hospital level, the economic evaluation will take a health 
service provider perspective. The comparatively small personal costs to patients and broader 
societal costs are highly unlikely to impact on the feasibility and cost-effectiveness, therefore 
will not be included in this analysis. All costs of TB investigations, TB treatment and 
associated toxicities, other investigations and treatment and HIV care and treatment during 
the study period will be estimated. 
Considering the complexities of diagnosis and treatment of HIV-associated TB for patients 
requiring hospital admission, we will estimate health service costs by combining the number 
of diagnostic tests, interventions and treatments with estimated unit-costs for each of the 
tests, procedures or interventions. Costs of hospital admission are likely to account for a 
large proportion of health service provider expenditure, and this will be calculated based on 
length of stay, and estimated unit-costs per day of hospitalisation. 
Once healthcare resource utilisation has been calculated, this will be combined with health 
service costs, which will be calculated using a predominately top-down approach. Resource 
utilization will be multiplied by the country-specific unit costs that including professional time, 
supplies, non-ART medications, as well as capital costs. We will derive ART and TB drug 
costs from the WHO Global Price Reporting Mechanism database. Quality of life measures 
will be recorded at enrolment and follow-up visits. 
In addition to conducting cost-effectiveness analyses, we will determine economic feasibility 
by estimating the 2-year and 5-year budgetary impact of implementation and scale-up of this 
intervention from a Ministry of Health perspective. Costing approaches will be the same for 
both study sites, however cost-effectiveness and budgetary impact will be calculated 
independently for South Africa (a middle-income country) and Malawi (a lower income 
country); professional costs in this countries will be different whereas drug costs will have 
less variation. Longer term health and cost-effectiveness will be estimated based on the 
Cost-effectiveness of Prevention of AIDS Complications International (CEPAC-I) computer 
simulation model. 
For the purpose of this economic analysis, the following data will be collected during the trial. 
For all patients:  
 length of hospital stay and subsequent health service use after discharge 
 number of HIV diagnostic tests required for enrolment 
 number of TB diagnostic tests and prescription of TB medications and resulting toxicities 
 details of HIV care, such as ART and CD4 cell count. 
For a subsample of the first 100 patients recruited at each trial site:  
 details of antibiotic and other prescription medicines during in-patient stay and at 
discharge 
 details of other (non-TB) diagnostic tests and procedures undertaken 
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Data will then be analysed, and if necessary repeated in an additional sample of patients to 
obtain sufficient precision around the cost estimates. 
For each trial site 
 The costs associated with each day of hospital admission 
 The costs associated with both TB and non-TB tests, procedures and treatments 
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11. STATISTICS 
11.1. Sample size justification 
 
Mortality risk: Recent unpublished data from the trial sites show mortality of HIV-infected 
medical in-patients during the hospital stay is 23% in Zomba and 21% in Edendale. We 
assume that the 56-day all-cause mortality (accruing between the date of admission and 56 
days follow-up) will lie in the range 25%-30% in the control arm. Despite using limited 
sampling techniques, recent post-mortem studies from South Africa (including at one of the 
trial sites), reported finding active TB in 50%-67% of medical HIV-infected in-patients who 
died [3,4]. Disease burdens are less well characterised in Malawi, but TB has consistently 
been identified as the leading cause of HIV related death throughout Africa accounting for 
32%-50% of deaths outside South Africa [3–7]. Thus, we estimate that between the two sites, 
approximately 40%-50% of total deaths in the control arm will be TB-related. 
Intervention: The addition of urine-based TB screening to the standard of care diagnostic 
screening increases the early diagnostic yield 3.0-fold (see Section 4.2) and sensitivity is 
highest among those with the lowest CD4 counts and poorest prognosis [45]. In background 
studies in South Africa, retrospective urine based testing was positive in all HIV-related TB 
deaths among both in-patients and out-patients [9,45]. Thus, we assume that all patients in 
the intervention arm at risk of TB-related death beyond the first day of admission will have 
rapid TB diagnosis and treatment initiation. However, it remains unknown what proportions of 
these deaths are preventable. In addition to the major effect of reducing TB-related mortality 
by increasing the yield and speed of TB diagnosis, early TB treatment might also directly 
increase survival via antimicrobial activity against gram-positive sepsis and indirectly by 
accelerating medical management and progression to start of ART.  
Effect size: Holtz et al.[46] reported on a study in South African hospitals with a before-after 
evaluation of implementation of the WHO algorithm for suspected smear-negative TB [47]. 
This complex intervention involved early initiation of empirical TB treatment among HIV-
infected in-patients in whom TB was suspected but unconfirmed. The observed reduction in 
mortality at 8 weeks was 47% (from 32% to 17%) and this was strongly associated with 
increased use of TB treatment [46]. The current trial is powered to detect a 20%-25% 
reduction in all-cause mortality. Assuming that half of the deaths are TB-related as shown by 
post-mortem studies, this equates to a 40%-50% reduction in TB-related mortality among 
those patients who do indeed have TB (consistent with the 47% mortality reduction observed 
by Holtz et al.). 
11.2. The Number of Participants 
 
The sample size calculation is based on the primary endpoint of mortality risk by 56 days 
from randomisation. Assuming an all-cause mortality of 25% in the control arm after 56 days 
of follow-up and a 2-sided type I error of 5%, inclusion of 1,300 patients per arm would 
provide 90% power to detect a 25% reduction in mortality and 80% power to detect a 20% 
reduction, allowing for loss to follow-up (LTFU) of 10%-15% by 56 days (see table 11.1). If 
the 56 day mortality risk in the control arm were unexpectedly lower (eg 20%), then this 
sample size would still be sufficient to provide 80% power to detect a 25% reduction in all-
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cause mortality with 15% LTFU. The study will have greater power for the secondary 
endpoint of time to death, measured up to 56 days from randomisation. 
 
 
Table 11.1. Sample-size calculations 
 
11.3. Data analysis plan 
 
A detailed statistical analysis plan will be written and approved by the DSMB prior to 
completion of enrolment. Analyses will be carried out under intention-to-treat practices and 
will be adjusted for site as a design factor. The primary outcome risk of all-cause mortality 
from randomisation to follow-up at 56 days will be analysed as a risk difference and odds 
ratio.  Imbalances in baseline covariates will not be tested statistically but if there appear to 
be any large imbalances then additional adjustment will be made for these in the analysis.      
The secondary outcome time from randomisation to all-cause mortality (follow-up to 56 days) 
will be compared between treatment arms using survival analysis with Kaplan-Meier curves 
and the Cox proportional hazards model where the intervention effects are summarised by 
rate ratio. Additionally the following secondary outcomes will be compared between 
intervention groups using risk differences and odds ratios: the proportion of patients with a 
diagnosis of TB, the proportion of patients receiving antibiotic treatment, the proportion of 
patients starting antiretroviral therapy (ART) among those not on ART at enrolment. The time 
from randomisation to the following outcomes will be compared between intervention groups 
using Cox regression: TB diagnosis, start of TB treatment, start of ART treatment for those 
not on ART at enrolment.    
Treatment decisions and outcomes will also be analysed by calendar period to assess for any 
changes in clinical practice over time. Differences in treatment effects by site will be 
investigated by considering interactions between randomisation group and site. The study is 
not powered for this so it would be an exploratory analysis. 
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12. DATA MANAGEMENT 
12.1. Source Data 
 
Source documents are where data are first recorded, and from which participants’ CRF data 
are obtained. These include, but are not limited to, hospital records (from which medical 
history and previous and concurrent medication may be summarised into the CRF), clinical 
charts, laboratory and pharmacy records, diaries, radiographs, and correspondence. 
CRF entries will be considered source data if the CRF is the site of the original recording (e.g. 
there is no other written or electronic record of data).  All documents will be stored safely in 
confidential conditions. On all trial-specific documents, other than the signed consent, the 
participant will be referred to by the trial participant number/code, not by name. 
12.2. Access to Data 
 
Direct access will be granted to authorised representatives from the Sponsor, host institution 
and the regulatory authorities to permit trial-related monitoring, audits and inspections. 
12.3. Data Recording and Record Keeping 
 
Case report forms (CRFs) will be completed in separate sections for each patient as follows, 
with data collected directly from the patient unless stated otherwise:  
 Eligibility and screening  
 Locator information 
 Baseline demographic and clinical information (collected from patients where possible, 
supplemented by information from hospital records) 
 Specimen collection 
 In-patient hospital follow-up (data collected from hospital records and/or clinical team) 
 Hospital discharge or in-patient death (data collected from hospital records and/or clinical 
team) 
 Out-patient follow-up, loss-to-follow-up or outpatient death (data from next-of-kin, relative 
or official register). 
The completeness and accuracy of each form will be checked by a second member of the 
study team and then countersigned following any amendments. CRFs will be completed as 
TeleForms (TeleForms Inc.) to allow direct entry of scanned data into a SQL Server Express 
database pre-programmed with logical data consistency checks. Once the TeleForm data 
have been scanned and imported into the database, validation will be performed through a 
visual inspection, with potential problematic values flagged for verification. Further validation 
will be performed to check for duplicates, validation, range checks and consistency. This will 
be overseen by the Data Coordinator at each site who will send encrypted data-files via 
secure internet connection to the study data-hub at the Malawi-Liverpool-Wellcome Trust 
(MLW) centre in Blantyre, Malawi.  
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Here the data from the two study sites will be merged into a single master database. The 
data manager at MLW will monitor data-completeness and quality and generate lists of data 
queries on a weekly basis which will be issued to each study team for review, clarification and 
feedback. At each study site, hard copies and electronic copies of all CRFs will be stored 
together with copies of all completed data query forms. All electronic databases will have 
daily scheduled backups, and a password will be required to gain access to data. The 
password-protected databases at the trial sites will be sent to LSHTM by Secure File Transfer 
Protocol (SFTP) on a weekly basis. Only trained staff will be granted access on a need-to-
see basis.  
Data will be stored using a unique study identifier allocated to each patient at enrolment into 
the study, name and any other identifying detail will NOT be included in any trial data 
electronic file. The code to anonymisation will be kept in a secure locked filing cabinet in a 
locked room, and access to this will be restricted to the PI and lead investigator at each site. 
All staff will be trained with respect to data management issues. 
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13.  MONITORING AND QUALITY ASSURANCE 
 
The trial will be conducted in accordance with the current approved protocol. The Investigator 
will ensure that this trial is conducted in accordance with the principles of the Declaration of 
Helsinki, with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 1996, 
MRC Guidelines for GCP and relevant regulations and standard operating procedures 
(SOPs).  
Prospective verification of data collected on case report forms will be done by local trial 
coordinators and data mangers. Furthermore, all data collected will be subject to random 
sampling for further verification of accuracy in relation to source documents, in addition to 
data quality checks inbuilt to the data recording systems. Any problems with data quality will 
be reported to the TSC and appropriate action taken, including increasing frequency of 
checks. Laboratory testing at both study sites will undergo periodic quality assurance 
procedures including proficiency testing of study diagnostics, for example testing of known 
smear-positive sputum samples and culture-negative sputum samples using Xpert MTB/RIF 
assay. All data monitoring and quality assurance processes will be outlined in detail in a 
separate SOP, and will be compliant with ICH GCP and MRC guidance.  
Regular monitoring will be performed according to ICH GCP. The London School of Hygiene 
& Tropical Medicine (LSHTM) will act as the main sponsor for the study and the study may be 
subject to audit by LSHTM under their remit as sponsor, or assessment by the regulatory 
authorities, to ensure compliance with protocols, GCP and applicable regulatory 
requirements. 
13.1. Trial Steering Committee 
 
The trial steering committee (TSC) will oversee the trial, monitor progress, advise the PI and 
investigator team, receive reports from the DSMB and report to the trial funders and sponsor. 
The TSC will include (as of March 2015): 
 Independent Chairman: Prof Anthony Harries (International Union Against TB & Lung 
Disease) 
 Independent members: Prof Andrew Ramsay (WHO / TDR) and Prof Frank Cobelens 
(University of Amsterdam, The Netherlands). 
 Investigators: Dr. Stephen D. Lawn (International PI); Dr. Douglas Wilson (Local PI at 
Edendale site); Dr. Joep van Oosterhout (Local PI at Zomba site). 
 Funder’s representative 
13.2. Trial Investigator Team 
 
This investigational team draws together an extremely strong team of local and international 
partners. This includes a wealth of clinical expertise in diagnosis and management of HIV-
associated TB; research expertise in clinical evaluation of TB diagnostics; the design and/or 
conduct of large randomised controlled trials; expertise in laboratory TB diagnostics; data 
management and analysis and strong relationships with local, regional and national partners 
such as National TB Programmes, National AIDS Commission, Ministries of Health and 
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National Health Laboratory Service. The structure of the investigator and operations study 
teams are outlined in appendix F, the investigator team and main responsibilities are as 
follows: 
 Dr. Stephen D. Lawn: Chief Investigator. Will oversee protocol development and all 
aspects of the international coordination and conduct of the trial, governance and data 
dissemination in close collaboration with Dr Ankur Gupta-Wright (International Study 
Coordinator). 
 Dr. Katherine Fielding (based at LSHTM) will be responsible for data management 
systems, data quality procedures and conduct the statistical analyses. 
 Prof Elizabeth Corbett (based at MLW, Malawi) will oversee for the central data-hub 
serving both of the study sites and provide technical support and QA of laboratories to the 
Zomba field-site. 
 Dr. Doug Wilson: Local PI (Edendale Hospital, South Africa) will take overall responsibility 
for the conduct of the study at this site. 
 Dr. Joep van Oosterhout (Dignitas International, Zomba Central Hospital, Malawi) will give 
input to protocol development and will take overall responsibility for the conduct of the 
study at this site. 
 Prof Mark Nicol Will design and coordinate the laboratory-based R&D component of the 
work 
at the University of Cape Town and provide technical advisory support regarding the 
laboratory diagnostics. 
 Prof Rochelle Walensky and Prof Ken Freedberg will plan and oversee all the economic 
analyses (cost-effectiveness and budgetary impact analyses). 
13.3. Ethical Considerations and Approvals 
 
The protocol, informed consent form, participant information sheet and any proposed 
advertising material will be submitted to Research Ethics Committees (REC) of the London 
School of Hygiene & Tropical Medicine, University of KwaZulu-Natal Biomedical Research 
Ethics Committee (BREC) and the College Of Medicine Research and Ethics Committee 
(COMREC) and host institutions for written approval. 
The Investigator will submit and, where necessary, obtain approval from the above parties for 
all substantial amendments to the original approved documents. 
Reporting: The investigators shall submit once a year throughout the clinical trial, or on 
request, an Annual Progress Report to the REC, host organisations and Sponsor.  In 
addition, an End of Trial notification and final report will be submitted to the REC, host 
organisation and Sponsor. 
Participant Confidentiality: The trial staff will ensure that the participants’ anonymity is 
maintained.  The participants will be identified only by initials and a unique study identifier on 
the CRF and any electronic database.  All documents will be stored securely and only 
accessible by trial staff and authorised personnel. The trial will comply with the Data 
Protection Act, which requires data to be anonymised as soon as it is practical to do so. 
Expenses and Benefits: Participants will receive a small nutritional food parcel during their 
in-patient stay in acknowledgement of the fact that some patients lack sufficient nutritional 
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input as in-patients and also as a good will gesture. Costs for time and travel expenses 
incurred when attending the 56 day post-randomisation follow-up visit will be reimbursed as 
appropriate. 
Risks to patients: Risk of harm to patients in this trial is low. The study requirement for 
samples of blood (for CD4count measurement), sputum and urine to be obtained from 
patients is not associated with risk to patient safety. We anticipate that patients in the 
intervention arm will benefit from urine-based screening due to increased diagnostic yield and 
acceleration of TB diagnosis. However, it is possible that such screening may inadvertently 
be harmful in the following ways: 
 A very small proportion of screening tests may yield false-positive results, leading to 
inappropriate treatment for TB (background studies report specificity >98% for urine 
diagnostic tests).  
 Rapid TB diagnosis may reduce the likelihood that patients receive an empirical course of 
simple antibiotics as part of the diagnostic work-up and therefore concurrent sepsis, if 
present, may not be treated 
 Rapid TB diagnosis may result in other concurrent pathologies being overlooked 
 Use of Xpert MTB/RIF may be associated with false-positive rifampicin resistance results 
in a very small proportion of patients, leading to inappropriate initiation of treatment for 
MDR-TB  
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14. FINANCE AND INSURANCE 
 
Funding: The trial is funded by Joint Global Health Trials (a jointly funded initiative by 
Medical Research Council, the UK Department for International Development and the 
Wellcome Trust). 
Insurance: The London School of Hygiene and Tropical Medicine (LSHTM) will act as the 
main sponsor for the study and holds public liability and clinical trial insurance policies which 
apply to this study which would operate in the event of any participant suffering harm as a 
result of their involvement in the research. 
15. PUBLICATION POLICY 
 
Academic dissemination: Data will be disseminated to local institutions as well as academic 
bodies within South Africa and Malawi with which the members of the investigational team 
already have links. Data will also be rapidly made available through presentations at relevant 
leading international conferences and regional conferences in southern Africa Primary data 
will be published in a timely manner in high impact peer reviewed journals. Findings will be 
summarised and made readily accessible on the institutional web-sites of the PI (LSHTM) 
and co-investigators. 
Engagement with Policy Makers: Policy-makers both nationally and internationally will be 
presented the findings of this study. These will include WHO, the STOP TB Partnership, the 
WHO Strategic and Technical Advisory Group for TB (STAG-TB), the WHO Strategic and 
Technical Advisory Group for HIV, the WHO TB/HIV taskforce and the WHO TB/HIV Working 
Group; the International Union Against TB and Lung Disease (IUATLD); National Ministries of 
Health of Malawi and South Africa, including their National TB Programmes and National 
AIDS Commissions / Councils. Malawi has established an innovative Knowledge Translation 
Platform (KTP Malawi) within the Malawi Ministry of Health (MoH) and with support from 
Dignitas International. KTP Malawi engages national-level policymakers, researchers and 
implementers in a coordinated approach to enhance the generation and utilization of the 
findings from health-sector research in Malawi. KTP Malawi has received official 
endorsement from the Malawi Ministry of Health's Senior Management Team. The trial would 
utilize this novel knowledge translation forum along with the more traditional methods of 
engaging with national level policymakers such as technical working groups to maximize the 
dissemination and policy impact of the trial. 
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Rapid Urine-Based Screening for Tuberculosis to Reduce AIDS-Related 
Mortality in Hospitalized Patients in Africa (STAMP) Trial 
INFORMATION ABOUT THE RESEARCH 
What you should know about this research study: 
 This information sheet is so that you can read about the purpose, risks and benefits of this 
research study. 
 Taking part is voluntary, and you have the right to refuse. 
 If you agree to take part now, you can change your mind at any time in the future.  
 Please read this information sheet carefully, and ask any questions before you make a 
decision. 
What is the study for? 
HIV is the virus that causes AIDS, and we know HIV increases the chances of you developing 
tuberculosis (TB). TB can be very difficult to diagnose in people living with HIV. We are doing 
a research study to see if using a new test for TB (done on a urine sample) on all people 
admitted to hospital who are living with HIV can help us diagnose and treat TB more quickly 
and help improve patients’ health. A study has shown one urine TB test (called TB-LAM) 
improved health when it was used in patients with HIV admitted to hospital and who were 
suspected of having TB. 
The research is taking place in South Africa and Malawi. The research team is from Malawi-
Liverpool-Wellcome Trust Research Centre in Blantyre, Dignitas International NGO in Zomba, 
Malawi, Edendale Hospital in KwaZulu-Natal, South Africa and London School of Hygiene & 
Tropical Medicine. 
 
Why have I been asked to take part? 
You have been asked to take part because you need admission to hospital, and are HIV-
positive. If you do take part, you will be one of 2,600 people in this study. 
 
Who can’t take part? 
If you are less than 18 years old, if you have taken TB treatment in the last year or you live 
outside the study area you will not be able to take part. 
 
What do I have to do if I take part? 
If you do take part, you will be asked to provide a urine sample, a sample of sputum (if 
possible), and about 3-4 teaspoons (15-20mls) of blood. It will be decided by chance (like 
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tossing a coin) whether your urine is tested for TB or not. Half of the patients will have urine 
tests done and half will not.  
Sputum and urine test results will be given to the doctors and nurses looking after you. They 
will decide whether to treat you for TB or not, and will provide all your medical care. We will 
need to see you again in 2 months to find out about your health. 
Part of the urine and blood samples you give will be tested immediately, with the rest stored 
for a period of up to 5 years in a secure laboratory storage facility to be tested later as part of 
this study. After this time they will be destroyed. 
 
What are the benefits? 
If you do have TB, then by participating in this research you may be able to start treatment 
more quickly, but we cannot guarantee that you will receive any benefits from this study.  
Taking part will not cost you anything and all the tests will be done free of charge. There is no 
payment for you to take part in the study but we will provide a small, healthy food parcel for 
you and we will refund your costs for attending the follow-up appointment in 2 months’ time.   
 
What are the risks? 
The blood test may cause discomfort or a small bruise. The study is unlikely to lead to any 
harm. Occasionally laboratory tests for TB can give a wrong positive results (less than 1 in 
100 tests). This could lead you to starting TB treatment that is not needed, or a combination of 
drugs that is not the ideal choice for you. 
 
What information will be collected, and will it be kept private? 
Details about your health, your home situation and your hospital stay will be written down. 
All information collected is kept private and the records will not include your name. Only 
approved study staff or people regulating the study will have access to your information, which 
will be stored electronically. The study results may be published in a medical journal so that 
others can learn from them, but your personal information will not be included and there is no 
way you can be identified from it. The study data may be made available to other researchers 
so that it can be used to improve care, but your personal information will not be included and 
there is no way you can be identified form it. 
 
Do I have to take part? 
You do not have to take part, it is up to you to decide. You can change your mind about taking 
part at any time, you just need to let your doctor know. If you don’t want to take part, or decide 
 STAMP protocol version 1.6 30/JAN/2018 
CONFIDENTIAL  Page 54 of 62 
to pull out of the study, your doctors and nurses will still care for you and give you the best 
treatment they can.  
Who has approved the study? 
The organisations conducting the studies and at least 2 independent groups of people looking 
after your interests (Research Ethics Committees) have checked the study and agreed it is 
safe for you to participate.  
 
Who to contact with questions or problems? 
You can talk to your study nurse or doctor about the study. You can also speak to 
____________________________________________________ who is in charge of the 
study at your hospital. You are encouraged to ask any questions you wish before, during or 
after the study. You may also use the following telephone numbers if you still need more 
information.  
 
Research Nurse ___________________________________     
Tel no ___________________________________________  
 
Study doctor ______________________________________ 
Tel no ___________________________________________ 
 
What if something goes wrong? 
The London School of Hygiene and Tropical Medicine holds insurance policies which apply to 
this study.  If you experience harm or injury as a result of taking part in this study, you may be 
eligible to claim compensation without having to prove that the School is at fault.  This does 
not affect your legal rights to seek compensation. 
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been treated during the course of the study then you should immediately 
inform the local Investigator, _____________________________________. 
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Rapid Urine-Based Screening for Tuberculosis to Reduce AIDS-Related 
Mortality in Hospitalized Patients in Africa (STAMP) Trial 
CONSENT FORM FOR PATIENT/REPRESENTATIVE 
Local PI and contact details: 
 
YOU ARE MAKING A DECISION WHETHER OR NOT TO PARTICIPATE IN THIS STUDY.  
YOUR SIGNATURE INDICATES THAT YOU HAVE READ AND UNDERSTOOD THE 
INFORMATION PROVIDED ABOVE, HAVE HAD ALL YOUR QUESTIONS ANSWERED, 
AND HAVE DECIDED TO PARTICIPATE. 
 
 I have read and understood the participant information sheet [or have understood the 
verbal explanation] and had the chance to consider the information, ask questions and 
have had these answered 
 
 I understand that it is my choice to take part in this study, and that I am free to pull out at 
any time, without giving reason, and without my medical care or rights being affected 
 
 I understand my medical notes may be looked at by responsible individuals involved in the 
study, from the London School of Hygiene & Tropical Medicine or from regulatory 
authorities. I give permission for this. 
 
 I give my permission for data collected about me in this study to be used for future 
research, subject to further ethical approval (with all my personal information removed) 
 
 I agree to participate in the STAMP trial, and for data and samples to be stored and tested 
later as part of this study. 
 
Participant Consent: 
 
Name of Participant (Print) _______________________________________________  
 
 
Signature (or thumbprint/mark) of Participant _________________________________ 
           
 
Date________________________ 
 
 
Name of Person Obtaining Consent (Print) ____________________________________  
 
 
Signature of Person Obtaining Consent _______________________________________ 
 
 
 
Date________________________  
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If the participant is unable to sign.   
 
As an impartial witness, I confirm that all the information about the study was given 
and the participant consented to taking part. 
 
 
Impartial Witness Name: ________________________________________________       
 
 
 
Impartial Witness Signature: _____________________________________________ 
 
 
 
Date________________________ 
 
 
 
 
 
YOU WILL BE GIVEN A COPY OF THIS CONSENT FORM TO KEEP 
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19. APPENDIX C: SCHEDULE OF PROCEDURES 
 
 
 
Procedures 
 
Screening Enrollment During 
hospital 
admissiona 
56-day 
follow-up 
Confirm HIV-status and age     
Confirm no history of TB 
treatment in preceding 12 
months 
    
Informed consent      
Demographic information      
Clinical history     
TB symptoms     
Vital signs     
Height, weight and MUAC     
Quality of Life questionnaire      
Karnofsky score     
Blood sample 15mls (FBC, CD4, 
CRP)b     
Sputum samplec     
Urine sample (>50mls)d     
Issue TB results to responsible 
medical teame     
Clinical record review     
Follow-up visit questionnaire     
a Clinical record review will occur during inpatient admission on at least days 1,2,3,4,5,7, 10, 14, and 
every 4 days thereafter 
b Sample also to be stored, total volume of blood approx. 15mls     
c Spontaneously expectorated only   
d tested with (i) Determine TB-LAM and (ii) Xpert MTB/RIF assays (in the intervention arm only) 
e  Within 24 hours of randomiastion when possible 
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20. APPENDIX D: CLASSIFICATION OF ADVERSE EVENTS 
 
Below are the relevant sections of the Division of AIDS table for grading the severity of adverse 
events (published December 2004, clarification August 2009) ULN = Upper Limit of Normal ; LLN = 
Lower Limit of Normal. Only Grade 3 or 4 will be reported for this study. 
 
Definitions: 
Basic Self-care Functions: activities such as bathing, dressing, toileting, transfer/movement, 
continence, and feeding. 
Usual Social & Functional Activities: adaptive tasks and desirable activities, such as going to work, 
shopping, cooking, use of transportation, pursuing a hobby etc. 
 
CLINICAL 
PARAMETER GRADE 1 
MILD 
GRADE 2 
MODERATE 
GRADE 3 
SEVERE 
GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
 
SYSTEMIC 
Acute systemic 
allergic reaction  
Localized urticaria 
(wheals) with no 
medical intervention 
indicated 
Localized urticaria 
with medical 
intervention indicated 
OR Mild angioedema 
with no medical 
intervention indicated 
Generalized 
urticaria OR 
Angioedema with 
medical 
intervention 
indicated OR 
Symptomatic mild 
bronchospasm 
Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR 
laryngeal edema 
INFECTION 
Infection (any other 
than HIV infection) 
Localized, no 
systemic 
antimicrobial 
treatment indicated 
AND Symptoms 
causing no or 
minimal interference 
with usual social & 
functional activities 
Systemic antimicrobial 
treatment indicated 
OR Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities 
Systemic 
antimicrobial 
treatment 
indicated AND 
Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Operative 
intervention (other 
than simple 
incision and 
drainage) indicated 
Life-threatening 
consequences (e.g., 
septic shock) 
SKIN – DERMATOLOGICAL 
Cutaneous reaction 
– rash 
Localized macular 
rash  
Diffuse macular, 
maculopapular, or 
morbilliform rash OR 
Target lesions  
Diffuse macular, 
maculopapular, or 
morbilliform rash 
with vesicles or 
limited number of 
bullae OR 
Superficial 
ulcerations of 
mucous membrane 
limited to one site 
Extensive or 
generalized bullous 
lesions OR Stevens-
Johnson syndrome OR 
Ulceration of mucous 
membrane involving 
two or more distinct 
mucosal sites OR Toxic 
epidermal necrolysis 
(TEN) 
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CLINICAL 
PARAMETER GRADE 1 
MILD 
GRADE 2 
MODERATE 
GRADE 3 
SEVERE 
GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
 
GASTROINTESTINAL 
Nausea  Transient (< 24 
hours) or 
intermittent nausea 
with no or minimal 
interference with 
oral intake 
Persistent nausea 
resulting in decreased 
oral intake for 24 – 48 
hours 
Persistent nausea 
resulting in 
minimal oral intake 
for > 48 hours OR 
Aggressive 
rehydration 
indicated (e.g., IV 
fluids) 
Life-threatening 
consequences (e.g., 
hypotensive shock) 
Vomiting Transient or 
intermittent 
vomiting with no or 
minimal interference 
with oral intake 
Frequent episodes of 
vomiting with no or 
mild dehydration 
Persistent vomiting 
resulting in 
orthostatic 
hypotension OR 
Aggressive 
rehydration 
indicated (e.g., IV 
fluids) 
Life-threatening 
consequences (e.g., 
hypotensive shock) 
NEUROLOGIC 
Neurosensory 
alteration (including 
paresthesia and 
painful neuropathy) 
Asymptomatic with 
sensory alteration on 
exam or minimal 
paresthesia causing 
no or minimal 
interference with 
usual social & 
functional activities  
Sensory alteration or 
paresthesia causing 
greater than minimal 
interference with 
usual social & 
functional activities  
Sensory alteration 
or paresthesia 
causing inability to 
perform usual 
social & functional 
activities 
Disabling sensory 
alteration or 
paresthesia causing 
inability to perform 
basic self-care 
functions 
 
OCULAR/VISUAL 
Visual changes (from 
baseline) 
Visual changes 
causing no or 
minimal interference 
with usual social & 
functional activities 
Visual changes causing 
greater than minimal 
interference with 
usual social & 
functional activities 
Visual changes 
causing inability to 
perform usual 
social & functional 
activities 
Disabling visual loss in 
affected eye(s) 
 
 
Laboratory testing 
ALT (SGPT) 1.25 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 
AST (SGOT) 1.25 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 
Bilirubin (Total) 1.1 – 1.5 x ULN 1.6 – 2.5 x ULN 2.6 – 5.0 x ULN > 5.0 x ULN 
Creatinine 1.1 – 1.3 x ULN† 1.4 – 1.8 x ULN† 1.9 – 3.4 x ULN†  3.5 x ULN† 
Other clinical event not specified above 
Clinical adverse 
event NOT identified 
elsewhere in this 
DAIDS AE grading 
table  
Symptoms causing 
no or minimal 
interference with 
usual social & 
functional activities 
Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities 
Symptoms causing 
inability to perform 
usual social & 
functional activities 
Symptoms causing 
inability to perform 
basic self-care 
functions OR Medical 
or operative 
intervention indicated 
to prevent permanent 
impairment, persistent 
disability, or death  
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21. APPENDIX E: STRUCTURE OF THE STUDY TEAM 
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22. APPENDIX F: DIAGNOSTIC ACCURACY OF RAPID TESTS 
 
Summary of diagnostic accuracy for Xpert MTB/RIF assay (pulmonary specimens, 
extrapulmonary and urine) and Determine TB LAM. 
 
Source  Assay Description/populati
on tested 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Reference 
standard/notes 
Steingart 
et al 2014 
[48] 
Xpert 
MTB/RIF 
Pooled estimates from 
systematic review for 
pulmonary TB  
 
Pooled estimates from 
systematic review for 
pulmonary TB in HIV-
positive patients 
median pooled 
0.89 (0.85-
0.92) 
 
median pooled 
0.97 (0.70-
0.86) 
median pooled 
0.99 (0.98-
0.99) 
 
median pooled 
0.98 (0.96-
0.99) 
solid or liquid 
culture of sputum 
Denkinger 
et al 2014 
[10] 
Xpert 
MTB/RIF 
Pooled estimates from 
systematic review for 
extrapulmonary TB 
Lymph node 
0.81 (0.72-
0.88) 
 
Pleural fluid 
0.21 (0.09–
30.4) 
 
Cerebrospinal 
fluid 
0.63 (0.48–
0.76) 
 
Lymph node 
0.99 (0.95- 
1.00) 
 
Pleural fluid 
1.00 (0.99-
1.00) 
 
Cerebrospinal 
fluid 
0.99 (0.96–
1.00) 
 
composite 
reference 
standard 
Maynard-
Smith et al 
2015 [11] 
Xpert 
MTB/RIF 
Pooled estimates from 
systematic review for 
extrapulmonary TB 
median pooled 
0.83 (IQR 
0.68–0.94)  
median pooled 
0.98 (IQR 
0.89–1.00) 
solid or liquid 
culture 
Minion et 
al 2011 [20] 
Determine 
TB LAM 
Pooled estimates from 
systematic review in 
HIV-positive patients 
pooled 0.56 
(0.40-0.71) 
pooled 0.95 
(0.77-0.99) 
solid or liquid 
culture 
Lawn et al 
2012 [17] 
Determine 
TB LAM 
 
 
Xpert 
MTB/RIF 
Active screening 
of HIV-positive out-
patients using urine 
 
 
 
0.28 (0.19-
0.39) 
 
 
0.19 (0.11-
0.29) 
0.99 (0.97-
1.00) 
 
 
1.00 
liquid culture, 
using grade-2 
cut-off 
Peter et al 
2012 [18] 
Determine 
TB LAM 
Active screening 
of HIV-positive in-
patients who were TB 
suspects 
0.45 (0.39–
0.53) 
0.96 (0.89–
1.00) 
composite 
reference 
standard, using 
grade-2 cut-off 
Peter et al 
2012 [15] 
Xpert 
MTB/RIF 
Active screening 
of HIV-positive in-
patients who were TB 
suspects using urine 
0.48 (0.40-
0.57) 
0.98 (0.95-
1.00) 
liquid culture 
Lawn et al 
2014 [9] 
Determine 
TB LAM 
 
 
Xpert 
MTB/RIF 
Active screening 
of HIV-positive in-
patients 
 
Active screening 
of HIV-positive in-
patients using 
concentrated urine 
0.35 (0.26-
0.44) 
 
 
 
0.56 (0.47-
0.66) 
0.99 (0.97-
1.00) 
 
 
 
- 
liquid culture or 
Xpert positive 
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23. APPENDIX G: AMENDMENT HISTORY 
 
Amendment 
No. 
Protocol 
Version 
No. 
Date 
issued 
Author(s) of 
changes 
Details of Changes made 
1 V1.1 29/07/2015 Ankur Gupta-
Wright 
1.Ethics reference numbers and 
trial registration updated 
2. Section 8.3 informed consent 
minor edit of wording in response 
to BREC request 
3. Calcification that immunology 
sub-study will only take place at 
Malawi site (section 8.8)  in 
response to BREC request 
 
Version approved by BREC on 
09/09/2015 
2 V1.2 19/11/2015 Ankur Gupta-
Wright 
1. Addition of section 8.12, details 
of immunology sub-study for 
Zomba site 
 
 
3 V1.3 05/02/2015 Ankur Gupta-
Wright 
1. Addition of information in the 
background about the LAMRCT 
results 
2. Change to patient information 
sheet in light of results of 
LAMRCT 
4 V1.4 27/06/2016 Ankur Gupta-
Wright 
1. Addition of Dr Katherine 
Fielding as co-Chief 
Investigator 
2. Additional of six month follow-
up for vital status at Edendale 
site (section 8.9) 
3. Addition of section 8.13, details 
of the strain diversity sub-study 
for the Edendale site 
5 V1.5 14/07/2016 Ankur Gupta-
Wright 
1. Addition of section 8.14, details 
of the FASH ultrasound sub-
study for the Zomba, Malawi 
Site 
6 V1.6 30/01/2018 Ankur Gupta-
Wright 
1. Addition of sections 8.15 sub-
study for describing prevalence 
of unsuppressed viral loads. 
 
 
Protocol amendments must be submitted to the Sponsor for approval prior to submission to 
the REC committee. 
